COX6C is linked to drug resistance [42], while TFF3 serves as a marker of differentiation and progression in breast cancer, particularly in DCIS, where it reflects a differentiated and secretory phenotype [43]. This evidence concerns the gene COX6C and ductal breast carcinoma in situ.